BEAM
Beam Therapeutics Inc
24.50$
+0.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 581.9% | 44.3% | 1,144.6% | 739.4% | 660.6% | 337.4% | 1,322.8% | 1,202.0% | 1,131.9% | 5.0% | 34.8% | – | – | |
| -481.9% | 55.7% | -1,044.6% | -639.4% | -560.6% | -237.4% | -1,222.8% | -1,102.0% | -1,031.9% | 95.0% | 65.2% | 100.0% | 18.9% | |
| 581.9% | 44.3% | 1,144.6% | 739.4% | 660.6% | 337.4% | 1,322.8% | 1,202.0% | 1,131.9% | 87.0% | 329.3% | 19,407.3% | 261.9% | |
| 147.8% | 13.7% | 360.6% | 251.7% | 185.8% | 95.3% | 374.0% | 317.3% | 275.7% | 23.3% | 108.5% | 6,519.8% | 76.7% | |
| 147.8% | 13.7% | 360.6% | 251.7% | 185.8% | 95.3% | 374.0% | 317.3% | 275.7% | 110.3% | 403.0% | 25,927.1% | 261.2% | |
| -629.7% | 42.0% | -1,405.3% | -891.1% | -746.4% | -332.7% | -1,596.9% | -1,419.2% | -1,307.6% | -15.3% | -337.8% | -25,827.1% | -242.3% | |
| 73.9% | 3.8% | – | 120.5% | 85.0% | – | – | 145.6% | 112.4% | 9.3% | 31.1% | 1,528.0% | 24.9% | |
| -558.9% | 45.6% | -1,331.6% | -773.1% | -677.5% | -300.5% | -1,462.8% | -1,208.3% | -1,162.4% | 214.1% | -297.2% | -25,036.3% | -54.7% | |
| -101.0% | 0.4% | 72.7% | 0.3% | -38.4% | – | – | – | – | – | – | – | – | |
| -558.9% | 45.2% | -1,331.6% | -773.5% | -677.5% | -300.5% | -1,462.8% | -1,208.3% | -1,162.4% | 214.1% | -297.2% | -25,036.3% | -54.7% | |
| -528.7% | 47.3% | -1,258.3% | -725.8% | -639.1% | -282.4% | -1,388.8% | -1,142.8% | -1,105.1% | 228.4% | -279.5% | -25,513.9% | -38.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.